VJOncology Podcast

Breast Cancer Updates from SABCS 2024

In this week’s podcast, we will discuss the most recent developments in breast cancer from the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Join us as renowned experts exclusively speak with us on highly anticipated findings from clinical trials across different breast cancer subtypes.

Gaia Griguolo from University of Padova in Italy, first discusses the PATINA trial, which investigated the addition of palbociclib to anti-HER2 and endocrine therapy in HR+/HER2+ breast cancer and Puneet Singh from The University of Texas MD Anderson Cancer Center comments on the COMET trial, which compared active monitoring with surgical management in low-risk ductal carcinoma in situ (DCIS). Elisa Agostinetto from Jules Bordet Institute subsequently gives an overview of findings from the Phase II DECRESCENDO trial of anthracycline-free treatment for HER2-positive, HR-negative, node-negative early breast cancer. Icro Meattini closes this episode with results from the EUROPA and FAST-Forward studies.

Novel immune checkpoint targets beyond PD-1 and CTLA-4 in solid tumors

This week’s podcast from VJOncology brings you the latest updates on novel checkpoint inhibitors that target LAG-3, TIGIT, and TIM3 in solid tumors. Our panel of experts share the latest findings from their clinical trials that tested the efficacy of different immune checkpoint inhibitors in neoplastic tumors.

Myriam Chalabi from the Netherlands Cancer Institute shares results from the NICHE-2 and NICHE-3 trials on MMR-deficient colon cancer, and Girish Kulkarni from the University of Toronto discusses the cohort C section of the KEYNOTE-057 trial, followed by the potential role of TIGIT/LAG-3 inhibition for urothelial carcinoma treatment. Ghassan Abou-Alfa from the Memorial Sloan Kettering Cancer Center shares results from different trials on anti-TIGIT therapies in hepatocellular carcinoma. Diwakar Davar from the University of Pittsburgh School of Medicine concludes with main findings from the AMBER trial on cobolimab for the treatment of non-small cell lung cancer.

Antibody drug conjugates in gastrointestinal cancers

This week’s podcast from VJOncology brings you key updates in antibody drug conjugates (ADCs) for gastrointestinal cancer. Our expert panel discusses the potential of ADCs targeting HER2, CMET, and CEACAM5 in gastric and colorectal cancers.

Hear from experts Kohei Shitara (National Cancer Center Hospital East), Yelena Janjigian (Memorial Sloan Kettering Cancer Center), John Strickler (Duke Cancer Institute), and Scott Kopetz (MD Anderson Cancer Center) as they provide an overview of the latest in ADCs for gastrointestinal cancers. Highlights include novel treatment strategies in HER2-expressing gastric cancer, findings from the DESTINY-Gastric03 and ABBV-400 trials, and the role of CEACAM5-targeting ADCs in colorectal cancer.

Novel therapeutics in PD-1 refractory melanoma

This week’s podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison Betoff Warner (Stanford University, Stanford, CA), Andrew Furness (Royal Marsden Hospital, London, UK), Anna Di Giacomo (University Hospital of Siena, Siena, Italy), María Vieito (Vall d’Hebron Institute of Oncology, Barcelona, Spain), and Yana Najjar (UPMC Hillman Cancer Center, Pittsburgh, PA), as they share insights into cutting-edge therapies and trials.

Highlights include the FDA approval of TIL therapy in metastatic melanoma, early findings on off-the-shelf T-cell therapy, and results from the NIBIT-ML1 trial (NCT04250246) investigating a triple combination of ipilimumab, nivolumab, and ASTX727. Discover updates from the FIRELIGHT-1 study (NCT04985604) on tovorafenib and its efficacy across solid tumors, and learn about challenges in treating acryl and mucosal melanoma from the IGNYTE trial (NCT03767348) of RP1 and a Phase II trial (NCT04493203) of nivolumab with axitinib.

Climate Change and Other Environmental Factors on Lung Cancer Risk at WCLC 2024

In this week’s podcast, we explore the critical links between environmental factors and lung cancer risk, focusing on the impacts of climate change, pollution, and exposure in conflict zones. Join us as we hear from experts Felipe Roitberg, MD, Brazilian Hospital Services Company (EBSERH), Brasília, Brazil, and Leticia Nogueira, MD, American Cancer Society, Palm Harbor, FL.

They share their insights from the IASLC 2024 World Conference on Lung Cancer, highlighting the challenges and innovative solutions emerging from resource-scarce communities worldwide. Discover how climate change affects every stage of cancer care, from prevention to treatment, and the importance of addressing disparities in healthcare access.

GI updates from ESMO 2024

This week’s podcast from VJOncology brings you key updates in gastrointestinal cancer from the European Society of Medical Oncology (ESMO) 2024 annual meeting, which took place in Barcelona, Spain.

Hear from experts, Jessie Elliot (Trinity St. James’s Cancer Institute), Myriam Chalabi (Netherlands Cancer Institute), and Changhoon Yoo (Asan Medical Center) as they discuss the latest in biliary tract and colon cancers, as well as gastric and gastroesophageal junction adenocarcinoma. Highlights include findings from the TOPGEAR trial, extended follow-up results from the NICHE-2 and the NICHE-3 trials, as well as findings from the NIFTY and NALIRICC studies. 

Updates in the management of refractory colorectal cancer

In this week’s podcast, we bring you the latest developments in the field of refractory colorectal cancer. We are joined by Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain; Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany; Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy; and Cristina Smolenski, MD, Gustave Roussy, Villejuif, France.

We’ll hear about the current treatment landscape for refractory metastatic colorectal cancer, especially in the third-line settings, updates from the SOREGATT trial, which assessed regorafenib with chemotherapy in pretreated colorectal cancer, and the emerging role of fruquintinib, a selective VEGFR inhibitor, in patients who progress on regorafenib.

ESSO 43 Highlights

In this podcast, we bring you exclusive insights from the 43rd Congress of the European Society of Surgical Oncology (ESSO 43), held in Antwerp, Belgium. We will be joined by Isabel Rubio, MD, PhD (Vall d'Hebron University Hospital, Barcelona, Spain), who discusses the dual focus of modern cancer surgery and the transformative impact of robotic surgery; Sylvie Bonvalot, MD, PhD, HDR (Institut Curie, Paris, France), recipient of the ESSO Lifetime Achievement Award 2024, who reflects on her extensive experience with desmoid tumors and sarcoma surgery; and Mitsuru Sasako, MD, PhD (Yodogawa Christian Hospital, Osaka, Japan), recipient of the ESSO Gold Medal 2024, who shares remarkable cases in gastric cancer surgery.

We will hear about the latest advancements in surgical oncology, innovative techniques that enhance patient quality of life, and the significance of collaboration in the field. Additionally, we will discuss the evolution of treatment strategies for desmoid tumors and sarcomas, including active surveillance and limb salvage surgery, and the importance of personalized treatment approaches.

For more exclusive content on ESSO 43, visit VJOncology.com.

Highlights from ESMO 2024

In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany.

We’ll hear about final overall survival results from the Phase II KEYNOTE-522 trial (NCT03036488) of pembrolizumab in triple-negative breast cancer, updates from the Phase III NADINA trial (NCT04949113) of ipilimumab and nivolumab in melanoma, and findings from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in urothelial carcinoma, as well as the Phase III NIAGARA trial (NCT03732677) of neoadjuvant immunotherapy in muscle-invasive bladder cancer. Other highlights include data from the Phase III MARIPOSA-2 trial (NCT04487080) of amivantamab in EGFR-mutant lung cancer, the Phase III KEYNOTE-A18 (NCT04221945) study in cervical cancer, and the Phase III POD1UM-303 trial (NCT04472429) of retifanlimab in squamous cell anal carcinoma.

Subscribe to our podcast on Apple Podcasts, Podbean, and Spotify, and join the conversation on X (formerly Twitter) @VJOncology. For more exclusive content on ESMO 2024, visit vjoncology.com.

Latest updates in managing brain metastases

In this podcast, we bring you the latest insights into managing brain metastases, with expert commentary from Manesh Mehta, MD, Miami Cancer Institute, Miami, FL; Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL; Gaia Griguolo, MD, University of Padova, Padova, Italy; Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel; and Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China,.

We will cover key findings from the Phase III METIS trial (NCT02831959), which explored Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer and brain metastases. Other topics include the complexities of managing symptomatic brain metastases in melanoma, new advances in breast cancer treatment with anti-HER2 agents, and the role of radiotherapy in preserving cognitive function. Finally, we'll discuss data from the DESTINY-Breast01, -02, and -03 trials (NCT03248492, NCT03523585, NCT03529110) on the CNS efficacy of trastuzumab deruxtecan (T-DXd).

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit VJOncology.com.